Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Hepatology
•
Hepatology
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
Related Questions
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
What is your strategy to manage pruritus in patients with cholestatic liver disease?
How do you approach the workup for a patient with imaging showing features suggestive of cirrhosis?
At what BMI or waist-circumference threshold do you opt to move from Fibroscan to other NILDA for fibrosis assessment?
Is there a serum ammonium level for which you recommend initiation of dialysis in a patient with hepatic encephalopathy?
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
How do you balance the need for diuretics from a volume perspective (Ex: ascites, edema) in decompensated cirrhotic patients and progressive renal dysfunction? Do you opt for "accepting" a higher creatinine and worsening renal dysfunction for more euvolemia? How would this change your practice if a patient was a transplant candidate?
When giving albumin challenge, for acute kidney injury with suspected hepatorenal syndrome, do you administer a single dose daily or split the dose of albumin?
Do you recommend starting naltrexone at discharge for alcohol use disorder in patients with decompensated cirrhosis secondary to alcohol use?
